Abstract
In the recent years many advances have been achieved in the field of the treatment of lung cancer; with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.
Keywords: Lung Cancer, non-small cell lung cancer, small cell lung cancer, elderly patients, surgery, radiotherapy, chemotherapy, adjuvant treatment, locally advanced nsclc, metastatic lung cancer, clinical trials, multimodality treatment, cutoff point, geriatric oncology, comprehensive geriatric assessment.
Anti-Cancer Agents in Medicinal Chemistry
Title:Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know
Volume: 13 Issue: 9
Author(s): Alessandra Bearz, Massimiliano Berretta, Arben Lleshi, Eleonora Berto and Umberto Tirelli
Affiliation:
Keywords: Lung Cancer, non-small cell lung cancer, small cell lung cancer, elderly patients, surgery, radiotherapy, chemotherapy, adjuvant treatment, locally advanced nsclc, metastatic lung cancer, clinical trials, multimodality treatment, cutoff point, geriatric oncology, comprehensive geriatric assessment.
Abstract: In the recent years many advances have been achieved in the field of the treatment of lung cancer; with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.
Export Options
About this article
Cite this article as:
Bearz Alessandra, Berretta Massimiliano, Lleshi Arben, Berto Eleonora and Tirelli Umberto, Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660353
DOI https://dx.doi.org/10.2174/18715206113136660353 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Nanosystems for Cancer Therapy
Current Cancer Therapy Reviews Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Natural and Engineered Cystine Knot Miniproteins for Diagnostic and Therapeutic Applications
Current Pharmaceutical Design Nanobiotechnology: An Efficient Approach to Drug Delivery of Unstable Biomolecules
Current Protein & Peptide Science Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Oncolytic Viruses: Whats Next?
Current Cancer Drug Targets Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer
Combinatorial Chemistry & High Throughput Screening Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3- Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4- Benzotriazine-1-Oxide Moiety
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest By Topo I-Mediated DNA Damage
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Current Cancer Drug Targets New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry